eISSN: 1731-2531
ISSN: 1642-5758
Anaesthesiology Intensive Therapy
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

vol. 53
Review paper

Comprehensive assessment of the aortic valve in critically ill patients for the non-cardiologist. Part II: Chronic aortic regurgitation of the native valve

Jeroen Walpot
1, 2
Guy L. Vermeiren
1, 3
Amar Al Mafragi
Manu L.N.G. Malbrain
4, 5

Department of Cardiology, Zorgsaam Hospital, Terneuzen, the Netherlands
Faculty of Health Siences and Medicine, University of Antwerp, Wilrijk, Belgium
Department of Intensive Care, Zorgsaam Hospital, Terneuzen, the Netherlands
International Fluid Academy, Lovenjoel, Belgium
Faculty of Engineering, Department of Electronics and Informatics, VUB, Brussels, Belgium
Anaesthesiol Intensive Ther 2021; 53, 1: 55–68
Online publish date: 2021/03/31
Article file
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Aortic regurgitation (AR) is caused by incomplete diastolic closure of the aortic valve (AV). Diastolic regurgitation towards the left ventricle (LV) causes LV volume overload, resulting in eccentric LV remodelling. The Framingham Study has reported a prevalence of traceable AR by echocardiography of 13.0% in men and 8.5% in women in the study population [1], with moderate and severe AR occurring in 0.5% of the total study population [2]. This review intends to give a comprehensive overview of the assessment of AR for clinicians working in fields other than cardiology. Echocardiography is the first line technical examination in assessment of AR, allowing a bedside approach to ICU patients. We focus on the underlying concepts and assumptions of calculating regurgitant volumes, regurgitant fraction (RF), and effective regurgitant orifice area (EROA). Qualitative and semiquantitative AR severity grading systems, used in echocardiography, are discussed. In this overview, we highlight that the final AR severity grading does not rely on one single echo parameter, but requires integration of information, obtained from 2D, M-mode, and Doppler colour flow mapping (CFM). Consistency between the different pieces of information is warranted.
Echocardiography also provides the key information regarding timing of surgical treatment of AR. Besides the AR severity grading, LV diastolic and diastolic dimensions, LV ejection fraction (LVEF), and the dimensions of the aortic root and ascending aorta can be measured. AR severity assessment may be challenging, requiring multimodality imaging. We overview the strengths and disadvantages of CMR, strain imaging and transoesophageal echocardiography.

Aetiology of aortic regurgitation

Most authors have classified the aetiology of AR into two main classes: AV leaflet abnormalities and aortic root abnormalities. This classification is sensible, as each entity requires a different treatment strategy. The most common aetiologies are listed below [3]:
Leaflet abnormalities:
• congenital bicuspid AV,
• rheumatic valve disease,
• atherosclerotic valve disease,
• myxomatous valve disease,
• infective endocarditis.
Aortic root abnormalities:
• hypertensive aortic root dilatation,
• cystic medial necrosis,
• Marfan’s syndrome,
• aortic dissection.
Rheumatic, bicuspid, and atherosclerotic disease were discussed in part I [4]. Endocarditis may induce AR either by obstruction of the diastolic closure of the AV by the vegetation, or by perforation of the leaflet. Even when the valve cusps are normal, dilatation of the aortic root may cause AR due to geometric alteration in the supporting structures of the leaflets [3]. Annular dilation – dilation at the base of the aortic root – results in AR due to reduced coaptation of the AV leaflets. Normally, there is an area of overlap between the leaflets, the so-called apposition zone. Therefore, mild dilatation of the aortic root may occur without or with only mild AR. Chronic hypertension, cystic medial necrosis, syphilis and Marfan’s disease may cause annular dilation. Aneurysm of the membranous septum (AMS) with ventricular septal defect (VSD) is often associated with AV prolapse and AR [5]. In patients with AMS and VSD, surgical resection of AMS with closure of the VSD is indicated to prevent progression of the AR [5, 6].

Pathophysiology and symptoms


Chronic AR causes LV volume overload, resulting in eccentric remodelling with increasing LV mass. According to the law of Laplace, LV wall stress = (LV pressure × radius)/LV wall thickness. As a compensatory mechanism to reduce the wall stress caused by LV dilation in patients with severe AR, LV wall thickening may occur, with a further subsequent rise in LV mass (Figure 1). To maintain cardiac output, the stroke volume needs to increase to compensate for the aortic regurgitant flow. The left ventricular ejection time will increase with subsequent reduction of diastolic time. The increased systolic workload will result in higher myocardial oxygen consumption. Another pathophysiological feature of severe AR is increased systolic blood pressure (due to the above-described increased stroke volume) and reduced diastolic blood pressure, due to the aortic regurgitant volume returning to the receiving dilated LV cavity. The coronary perfusion pressure (CPP), the driving force of myocardial perfusion, is the difference between diastolic pressure (DP) and LV end-diastolic pressure (LVEDP). Thus, the formula is: CPP = DP – LVEDP Due to the reduced DP, the CPP will decrease, resulting in reduced myocardial oxygen supply. Initially these compensatory mechanisms will function well. Ultimately, LV dysfunction will occur and the disbalance between increased myocardial oxygen consumption and reduced myocardial oxygen supply will result in ischemia. Ischemia will induce further LV dysfunction. Finally, symptoms of congestive heart failure and/or angina pectoris will present.


Ultimately, most patients with severe AR will develop symptoms, with reported average rates of symptom onset of 5–6% per year in prospective studies [7, 8]. Usually, the initial symptoms are exertional dyspnoea and reduced exercise tolerance [9]. Severe AR is associated with a small risk of sudden death, occurring in 2–4% of patients over 7–8 years of follow up [9]. However, in the setting of ICU medicine, the diagnosis of severe AR is merely an occasional finding in the echocardiographic assessment of the LV function rather than a primary clinical consideration, except in the case of infective endocarditis.

Echocardiographic assessment of aortic regurgitation

2D and M-mode echocardiography

2D and M-mode echocardiography contribute to the assessment of AR grading:
• longstanding severe AR will result in LV dilatation (see pathophysiology section). The left ventricular end-diastolic diameter (LVEDd) is one of the criteria in the assessment of AR severity as well as the decision to refer the patient with AR for aortic valve replacement (AVR) [10] (Figure 2);
• M-mode may show fluttering of the anterior mitral valve leaflet due to severe AR (Figure 3); a colour M-mode image through the LVOT may give an impression of AR jet width (Figure 4);
• quantification of the LVEF is an essential part of the assessment of AR, as deterioration of LV systolic function is one of the key elements in clinical decision making, regarding timing of AVR.

Continuous wave (CW) regurgitation flow

Qualitative assessment of the CW regurgitant flow signal is useful to assess the severity of AR in 3 ways: 1. Density of the CW regurgitant flow: The Doppler signal intensity is proportional to the number of red blood cells contributing to the regurgitant signal. The ultrasound beam is relatively broad. Most of the regurgitant flow can be detected by adequate positioning of the ultrasound beam. The denser the regurgitant CW signal is, the greater is the AR volume. Comparison of the density of the CW signal between the antegrade and regurgitant flow is particularly useful. If the signal density of the regurgitant flow nearly equals the density of the antegrade flow, this implies severe AR. Conversely, a low density of the CW regurgitant flow reflects mild AR. A signal intensity between both former scenarios reflects moderate AS (Figure 5).
2. CW of the antegrade flow: In AR, the antegrade flow through the AV must increase, as the total flow through the AV is the sum of the net forward flow and AR flow. Thus, the antegrade flow and its peak CW velocity will increase when significant AR is present. Of course, the differentiation with concurrent AS should be made.
3. Shape of the CW regurgitant signal: The shape of the AR velocity curve depends on the time course of the diastolic pressure across the AV. When the LV diastolic pressure is low and aortic diastolic pressure is normal, the pressure gradient remains large throughout the diastole, with a slow decline of the transvalvular gradient. This principle is semi-quantified by measuring the pressure half time (see below: Pressure half time). In acute AR, there will be a rapid equalization of the pressure, with a more rapid decline in diastolic regurgitation (Figure 6).

Pressure half time

Measurement of pressure half time (PHT) is a semiquantitative method to assess AR severity (Figure 6). Essentially, this method is a quantification of the shape of the AR regurgitant shape (see above: Shape of the CW regurgitant signal). By definition, PHT is the time for the peak pressure to drop to half its value. It is also the time interval for the peak velocity to reach the velocity that equals the peak velocity divided by (= 1.4) [11, 12]. The PHT is always proportional to the deceleration time (DT) [13]: PHT = 0.29 × DT In patients with severe AR, the PHT becomes significantly shorter (PHT < 200 ms) [13].

Volumetric assessment of aortic regurgitation

Volumetric assessment of AR is based on the principle of preservation of flow. Preservation of flow, expressed in the continuity equation, requires that the blood volume that enters the LV equals the blood volume that leaves the LV, in the assumption that there is no mitral regurgitation (Figure 7). In the case of AR, this implies that the left ventricular outflow tract flow equals the sum aortic regurgitant flow (aortic reg. flow) and mitral valve flow (MV flow), during diastole. Thus: Aortic Reg V = LVOT flow – MV flow In part I, the calculation of the LVOT stroke volume was explained: LVOT flow = (DLVOT/2)2 × π × VTILVOT Similarly, the MV flow can be calculated using VTIMV and MV annulus diameter (DMV annulus): MV flow = (DMV annulus/2)2 × π × VTIMV The continuity equation for AR can be rewritten as follows (Figure 8): Aortic Reg V = LVOT flow – MV flow or Aortic Reg V = ((DLVOT/2)2 × π × VTILVOT) – ((DMV annulus/2)2 × π × VTIMV) Finally, the RF can be calculated: RF = (Aortic Reg V/LVOT stroke volume) × 100% or RF = (Aortic Reg V/(DLVOT/2)2 × π × VTILVOT)) × 100% Flow volume is the product of area and VTI. Thus, the EROA is calculated by dividing regurgitant volume by VTIAR

Proximal isovelocity surface area

Proximal isovelocity surface area (PISA) is another method that can be used to calculate the EROA [14, 15]. Especially in mitral regurgitation, this method is used in daily clinical practice in the echo laboratory. However, this principle can be used to assess the EROA in AR but is rarely used in the emergency and ICU settings. As the blood flow nears the regurgitant orifice, flow converges towards the EROA, with formation of multiple hemispheric shells of the same velocity (isovelocity). The flow rate at the surface of such a hemispheric shell is the same as the flow through the EROA, due to the principle of preservation of flow. By adjusting the Nyquist limit of the colour flow map (CFM), the velocity at the surface can be determined [13]. The radius (r) of the PISA can be measured (Figure 9). The area of the hemisphere is calculated as 2π(r)2. Thus, flow rate at the hemisphere can be expressed as follows: Flow rate = 6.28 × r2 × Aliasing velocity (a) The flow through the EROA a valve can be determined by multiplying EROA with the peak velocity through the EROA. Flow rate = EROA × Peak velocity across the valve (b) Due to preservation of flow (a) equals (b). In the case of AR, this equation can be expressed: 6.28 × r2 × Aliasing velocity = EROA × Peak AR velocity EROA = (6.28 × r2 × Aliasing velocity)/Peak AR velocity

Colour flow imaging of the aortic regurgitation jet width

Colour flow imaging of AR is best performed in the parasternal long-axis and short-axis views (by TTE windows) or the LVOT view (by the trans­oesophageal echocardiography [TEE] window at 135 degrees) [13]. Basically, colour flow imaging is pulsed Doppler ultrasound with different signal processing and display [3]. This semiquantitative method has been proven to be extremely useful in severity assessment. By integrating the data from different tomographic planes, the three-dimensional shape of the regurgitant jet can be estimated. A scale from 0 to 4+ describes the AR severity, with 0 being no regurgitation, 1+ mild regurgitation, 2+ and 3+ being moderate AR and 4+ being severe AR (the regurgitant jet reaches the apex and nearly fills the LV) [3] (Figure 10).

Vena contracta

The width of the vena contracta (VC-W) is the smallest area in the regurgitant flow, between the proximal laminar flow acceleration zone and the distal turbulent regurgitant jet spray (Figure 11). The EACVI (European Association of Cardiovascular Imaging) Echo Handbook defines a VC-W > 6 mm as a criterion for severe AR [16]. Studies have demonstrated that the measurement of the VC-W is simple and reproducible [17–19]. It has been stated that this method is less dependent on loading conditions in assessing AR severity. The vena contracta jet shape is not always circular. Therefore, the VCW measurement may over- or underestimate AR severity. Three-dimensional (3D) echocardiography can directly measure the vena contracta area (VCA). Not surprisingly, studies have shown that 3D VCA measurement is superior to VC-W measurement for AR quantitation [20–24].

Diastolic flow reversal in the descending aorta

Holodiastolic flow reversal in the descending thoracic aorta (see Figure 12A and B) and in the abdominal aorta (see Figure 12C) are associated with AR severity. Holodiastolic flow reversal in the abdominal aorta, measured from a subcostal window, is sensitive (100%) and specific (97%) for severe AR [3]. Holodiastolic flow reversal in the descending thoracic aorta is also very sensitive, but less specific, and may be seen in some patients with moderate AR [3].

Diastolic filling pattern

The basics of echo Doppler assessment of diastolic function and LV loading were discussed in a previous paper [25]. Part I recaps the most relevant filling patterns [4]. A restrictive mitral flow pattern is present in acute severe AR.

Integration of all transthoracic echocardiography measurements

The severity of AR is determined by integrating of all pieces of information obtained from the TTE. The assessment of severity of AR includes not only qualitative and quantitative grading of the AR, but also presence of eccentric remodelling and the diastolic filling pattern. The famous echocardiography textbook of Oh et al. lists the criteria for severe AR as follows [13]:
• regurgitant jet width/LVOT diameter ratio ≥ 60%,
• regurgitant jet area/LVOT area ratio ≥ 60%,
• AR PHT ≤ 250 ms (PHT < 200 ms according to the most recent guidelines),
• restrictive transmitral diastolic filling pattern (usually in the acute setting),
• holodiastolic flow reversal in the descending aorta,
• dense CW doppler AR signal,
• RF ≥ 50%,
• regurgitant volume ≥ 60%,
• effective regurgitant orifice (ERO) ≥ 0.3 mL,
• in chronic AR: LV end-diastolic diameter ≥ 7.5 cm,
• mild AR is defined as regurgitant jet width/LVOT diameter ratio ≤ 30%, regurgitant jet area/LVOT area ratio ≤ 30%, AR PHT ≤ 250 ms, mild early flow reversal in the descending aorta, faint CW doppler AR signal, RF ≤ 30%, ERO ≤ 0.1 cm2, and LV end-diastolic diameter ≤ 6.0 cm. Table 1 lists the criteria for severe AR from the ESC guidelines of valvular heart disease (2017) and/or The EACVI Echo Handbook [10, 16].

Role of transoesophageal echocardiography

TEE is clinically useful in the assessment of AR in many ways. TEE is helpful in determining the aetiology of AR.
1. In patients with AR, leaflet abnormalities should be differentiated from AR secondary to aortic root abnormalities. The AV, the aortic root and the first part of the ascending aorta can be well visualized by TEE. 2. Infective endocarditis is a cause of severe AR. TEE is superior to TTE in depicting complications of infective endocarditis that require (semi)-urgent surgical intervention.
• The size of the vegetation: patients with vegetations > 1 cm are at higher risk of embolic complications [26–29].
• Perivalvular abscesses (Figures 13 and 14) and phlegmons can be better evaluated on TEE. These findings are alarm signs, with high mortality if not promptly treated.
• Paravalvular fistula and leaflet perforation can be better detected by TEE (Figures 13 and 14). • In infective endocarditis of the AV, the adjacent mitral valve (MV) may be involved. Rigorous inspection of the MV is required (Figure 15).
3. A bicuspid AV should be differentiated from a tricuspid AV. Inspection of the AV by TEE usually allows differentiation between bicuspid and tricuspid AV. However, in the case of severe calcification the differentiation may be challenging.
Finally, it should be emphasized that echo Doppler TEE cannot quantify the AR severity by the continuity equation, because the ultrasound beam cannot be aligned parallel to flow across the AV.

Echocardiography acquired strain imaging

While several studies have demonstrated that reduced LV global longitudinal strain (LV-GLS) is associated with reduced outcome after AVR in patients suffering from severe AS, this correlation is less well investigated in patients with AR. A study including 115 patients with AR and 55 control individuals demonstrated that lower resting values of LV-GLS in severe AR asymptomatic patients suggest early subclinical myocardial damage that seems to be closely associated with lower exercise capacity, greater pulmonary congestion, and blunted LV contractile reserve during stress [30].
Another series, examining patients undergoing AVR due to AR, sought a correlation between LV-GLS and outcome. In patients with ≥ 3+ chronic AR and preserved LVEF undergoing AVR, a baseline LV-GLS value worse than –19% was associated with reduced survival. Further, persistently impaired LV-GLS after AVR was associated with increased mortality [31].

New imaging modalities to assess aortic regurgitation

In part I, the advantages and pitfalls of CMR to AV lesions were discussed [4]. In the setting of ICU medicine, the beside approach of echocardiography is a major advantage [32–34] compared to CMR. Due to the limitations of the echocardiographic qualitative, semi-quantitative, and quantitative methods for the assessment of AR, current echocardiographic guidelines strongly recommend an integrative approach using multiple qualitative and quantitative methods to assess the AR severity grade. Not surprisingly, CMR acquired AR grading has gained interest in the medical community. Phase-contrast velocity mapping is used to determine the forward and reverse flow per cardiac cycle directly. Regurgitant volume is the difference between LV stroke volume from the LV measurements and forward aortic volume. From these the RF is calculated (regurgitant volume/forward volume × 100) [35]. Alternatively, the regurgitant volume can be calculated by cine assessment and comparison of LV and right ventricle (RV) stroke volumes, assuming there is no other valve disease [35, 36]. There is a moderate correlation between regurgitant volumes measured by echocardiography and CMR, but the observer variability is significantly lower with CMR [37].
The ESC guidelines recommend volumetric quantification of AR by CMR when the cardiac ultra­sound findings are equivocal regarding AR severity [10]. The role of cardiac CT in the assessment of native AR severity per se is limited. However, AR commonly co-exists with aortic dilatation, necessitating evaluation of the thoracic aorta by thoracic CT. Most recent cardiac CT research in the field of AV disease focusses on the question whether specific anatomical features, such as bicuspid AV and calcification severity, predict outcome (mortality, iatrogenic AR, …) after TAVR [38–41].

Invasive assessment of aortic regurgitation

Invasive evaluation of AR does not provide true quantitation of the AR, because it relies on aortic root angiography, which is a semiquantitative grading system, describing the degree of opacification of the LV by the regurgitant jet (Figure 16). By convention, the AR severity grading is defined as follows:
• grade 1: brief and incomplete ventricular opacification; clears rapidly;
• grade 2: moderate opacification of the ventricle that clears in less than 2 cycles; never greater than aortic root opacification;
• grade 3: opacification of the ventricle equal to aortic root opacification within 2 cycles; delayed clearing of ventricle over several cycles;
• grade 4: opacification of the ventricle almost immediately that is greater than that of the aortic root with delayed clearing of the ventricle.
Catheterization allows assessment of the aortic root size and the LVEF. Haemodynamic measurements indirectly assess the severity AR, by assessing the left ventricular (LVEDP) and cardiac output.

Treatment of aortic regurgitation

Indications for aortic valve surgery

The ESC guidelines of valvular heart disease (2017) divide the indications for AV surgery into two main categories: severe AR and aortic root disease (irrespective of the severity of AR) [10]. In patients with severe AR, the presence of symptoms, reduced LV EF, and LV size are the key elements in clinical decision making. According to these ESC guidelines, AVR/repair is indicated in severe AR, if [10]:
• surgery is indicated in symptomatic patients (Class I B),
• surgery is indicated in asymptomatic patients with resting LVEF ≤ 50% (Class I B),
• surgery is indicated in patients undergoing CABG or surgery of the ascending aorta or of another valve (Class I C),
• Heart Team discussion is recommended in selected patients in whom AV repair may be a feasible alternative to valve replacement (Class I C),
• surgery should be considered in asymptomatic patients with resting ejection fraction > 50% with severe LV dilatation: LVEDD > 70 mm or LVESD > 50 mm (or LVESD > 25 mm m-2 BSA in patients with small body size) (Class IIa B).
The ESC guidelines recommend surgery for aortic root disease (irrespective of the severity of AR) as follows [10]:
• AV repair, using the reimplantation or remodelling with aortic annuloplasty technique, is recommended in young patients with aortic root dilation and tricuspid aortic valves, when performed by experienced surgeons (Class I C);
• surgery is indicated in patients with Marfan syndrome who have aortic root disease with a maximal ascending aortic diameter ≥ 50 mm (Class I C);
• surgery should be considered in patients who have aortic root disease with maximal ascending aortic diameter:
– ≥ 45 mm in the presence of Marfan syndrome (Class IIa B),
– ≥ 50 mm in the presence of a bicuspid valve (Class IIa B),
– ≥ 55 mm for all other patients (Class IIa B);
• when surgery is primarily indicated for the AV, replacement of the aortic root or tubular ascending aorta should be considered when ≥ 45 mm, particularly in the presence of a bicuspid valve (Class IIa B).

Medical therapy

AR causes a volume and pressure overload state of the left ventricle as the increased stroke volume is ejected into the high resistance aorta [9]. From a physiological point of view, afterload reduction makes sense as it reduces the AR volume, and thus prevents further LV dilation. A study comparing nifedipine and digoxin in patients with severe AR and left ventricular dilation demonstrated that treatment with nifedipine was associated with a 6-year event-free survival rate of 85% compared to 65% in those in the digoxin group [42]. Small studies have shown that angiotensin converting enzyme (ACE) inhibitors slow the progression of LV dilation [43–47]. However, it has been advocated that vasodilator therapy may have deleterious effects as it may result in only a ‘cosmetic’ effect, masking the onset of significant symptoms or LV dysfunction [48]. The ESC guidelines [10] state that: ‘Medical therapy can provide symptomatic improvement in individuals with chronic severe AR in whom surgery is not feasible. In patients who undergo surgery but continue to suffer from heart failure or hypertension, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and beta-blockers are useful’ [49, 50]. Apart from AR due to infective endocarditis, the treatment of AR in the ICU will focus on treatment of congestive heart failure (reducing volume overload) and afterload reduction.


Inadequate diastolic closure of the AV causes AR. Diastolic regurgitation towards the LV causes LV volume overload, resulting in eccentric LV remodelling. Symptoms occur when the adaptation mechanisms can no longer handle the LV volume overload. TTE is the first line examination in the work-up of AR. A state-of-the-art overview of echocardiographic AR severity grading by 2D, M-mode, CFM, pulsed wave (PV) and continuous wave (CW) echo Doppler is provided. We summarize the key elements in the interpretation of echocardiographic AR severity grading in the form of take home messages (Tables 2 and 3). We emphasize that assessment of AR severity never relies on one single echocardiographic measurement, but requires integration of all pieces of information, obtained from all these echocardiographic modalities. Finally, we overview the criteria for valve surgery in AR. Besides severe AR, presence of symptoms, LVEF, LV dimensions, and aortic root/ascending aorta diameter are the key elements in timing surgical treatment. The role of vasodilator therapy in the treatment of AR is briefly discussed.


1. Financial support and sponsorship: none.
2. Conflicts of interest: MLNGM is a member of the Executive Committee of the Abdominal Compartment Society, formerly known as the World Society of Abdominal Compartment Syndrome (https://www.wsacs.org/). He is the inaugural President, a co-founder of the WSACS and the current Treasurer. He is a co-founder and the President of the International Fluid Academy (IFA). The IFA is integrated within the not-for-profit charitable organization iMERiT, International Medical Education and Research Initiative, under Belgian law. The content of the IFA website (http://www.fluidacademy.org) is based on the philosophy of FOAM (Free Open Access Medical education – #FOAMed). He is a member of the medical advisory Board of Pulsion Medical Systems (now fully integrated in Getinge, Solna, Sweden) and Serenno Medical (Tel Aviv, Israel), and consults for Baxter, Maltron, ConvaTec, Acelity, Spiegelberg and Holtech Medical.
The other authors have no potential conflicts of interest with regard to the contents of this review paper.


1. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999; 83: 897-902. doi:10.1016/S0002-9149(98)01064-9.
2. Akinseye OA, Pathak A, Ibebuogu UN. Aortic valve regurgitation: a comprehensive review. Curr Probl Cardiol 2018; 43: 315-334. doi:10.1016/j.cpcardiol.2017.10.004.
3. Otto CM. Textbook of Clinical Echocardiography. W.B. Saunders Company; 2000: 229-269.
4. Walpot J, Vermeiren GLJ, Al Mafragi A, Malbrain MLNG. Comprehensive assessment of the aortic valve in critically ill patients for the non-cardiologist. Part I: Aortic stenosis of the native valve. Anaesthesiol Intensive Ther 2021; 53: ???-???. doi: https://doi.org/10.5114/ait.2021.104550.
5. Yilmaz AT, Ozal E, Arslan M, Tatar H, Oztürk OY. Aneurysm of the membranous septum in adult patients with perimembranous ventricular septal defect. Eur J Cardiothorac Surg 1997; 11: 307-311. doi: 10.1016/s1010-7940(96)01058-5.
6. Walpot J, Peerenboom P, van Wylick A, Klazen C. Aneurysm of the membranous septum with ventricular septal defect and infective endocarditis. Eur J Echocardiogr 2004; 5: 391-393. doi: 10.1016/j.euje.2004.02.005.
7. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 1991; 84: 1625-1635. doi: 10.1161/01.CIR.84.4.1625.
8. Borer JS, Hochreiter C, Herrold EM, et al. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. Circulation 1998; 97: 525-534. doi: 10.1161/01.CIR.97.6.525.
9. Otto CM. Valve disease: timing of aortic valve surgery. Heart 2000; 84: 211-218. doi: 10.1136/heart.84.2.211.
10. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739-2791. doi: 10.1093/eurheartj/ehx391.
11. Hatle L, Angelsen B, Tromsdal A. Noninvasive assessment of atrioventricular pressure half-time by Doppler ultrasound. Circulation 1979; 60: 1096-1104. doi: 10.1161/01.CIR.60.5.1096.
12. Thomas JD, Weyman AE. Doppler mitral pressure half-time: a clinical tool in search of theoretical justification. J Am Coll Cardiol 1987; 10: 923-929. doi: 10.1016/S0735-1097(87)80290-5.
13. Oh JK, Seward JB, Tajik JA. The echo manual. In: The Echo Manual. 2nd ed. Lippincott Williams & Wilkins, Philadelphia 1999; 103-132.
14. Chen C, Koschyk D, Brockhoff C, et al. Noninvasive estimation of regurgitant flow rate and volume in patients with mitral regurgitation by doppler color mapping of accelerating flow field. J Am Coll Cardiol 1993; 21: 374-383. doi: 10.1016/0735-1097(93)90678-T.
15. Giesler M, Grossmann G, Schmidt A, et al. Color Doppler echocardiographic determination of mitral regurgitant flow from the proximal velocity profile of the flow convergence region. Am J Cardiol 1993; 71: 217-224. doi: 10.1016/0002-9149(93)90741-T.
16. Lancellotti P, Cosyns B. The EACVI Echo Handbook. Oxford University Press, Oxford 2016; 244-264.
17. Tribouilloy CM, Enriquez-Sarano M, Bailey KR, Seward JB, Tajik AJ. Assessment of severity of aortic regurgitation using the width of the vena contracta. Circulation 2000; 102: 558-564. doi: 10.1161/01.CIR. 102.5.558.
18. Willett DL, Hall SA, Jessen ME, Wait MA, Grayburn PA. Assessment of aortic regurgitation by transesophageal color Doppler imaging of the vena contracta: validation against an intraoperative aortic flow probe. J Am Coll Cardiol 2001; 37: 1450-1455. doi: 10.1016/S0735-1097(01)01114-7.
19. Messika-Zeitoun D, Detaint D, Leye M, et al. Comparison of semiquantitative and quantitative assessment of severity of aortic regurgitation: clinical implications. J Am Soc Echocardiogr 2011; 24: 1246-1252. doi: 10.1016/j.echo.2011.08.009.
20. Nozaki S, Mizushige K, Taminato T, Obayashi N, Matsuo H. New index for grading the severity of aortic regurgitation based on the cross-sectional area of vena contracta measured by color Doppler flow mapping. Circ J 2003; 67: 243-247. doi: 10.1253/circj.67.243.
21. Gonçalves A, Almeria C, Marcos-Alberca P, et al. Three-dimensional echocardiography in paravalvular aortic regurgitation assessment after transcatheter aortic valve implantation. J Am Soc Echocardiogr 2012; 25: 47-55. doi: 10.1016/j.echo.2011.08.019.
22. Mori Y, Shiota T, Jones M, et al. Three-dimensional reconstruction of the color doppler–imaged vena contracta for quantifying aortic regurgitation. Circulation 1999; 99: 1611-1617. doi: 10.1161/01.CIR.99.12.1611.
23. Shiota T, Jones M, Tsujino H, et al. Quantitative analysis of aortic regurgitation: real-time 3-dimensional and 2-dimensional color Doppler echocardiographic method – a clinical and a chronic animal study. J Am Soc Echocardiogr 2002; 15: 966-971. doi: 10.1067/mje.2002.120981.
24. Sato H, Ohta T, Hiroe K, et al. Severity of aortic regurgitation assessed by area of vena contracta: a clinical two-dimensional and three-dimensional color Doppler imaging study. Cardiovasc Ultrasound 2015; 13: 24. doi: 10.1186/s12947-015-0016-5.
25. Vermeiren GLJ, Malbrain MLNG, Walpot JMJB. Cardiac ultrasonography in the critical care setting: a practical approach to asses cardiac function and preload for the “non-cardiologist”. Anaesthesiol Intensive Ther 2015; 47 Spec No: s89-104. doi: 10.5603/AIT.a2015.0074.
26. Tischler MD, Vaitkus PT. The ability of vegetation size on echocardiography to predict clinical complications: a meta-analysis. J Am Soc Echocardiogr 1997; 10: 562-568. doi: 10.1016/S0894-7317(97)70011-7.
27. Di Salvo G, Habib G, Pergola V, et al. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol 2001; 37: 1069-1076. doi: 10.1016/S0735-1097(00)01206-7.
28. Cabell CH, Pond KK, Peterson GE, et al. The risk of stroke and death in patients with aortic and mitral valve endocarditis. Am Heart J 2001; 142: 75-80. doi: 10.1067/mhj.2001.115790.
29. Lutas EM, Roberts RB, Devereux RB, Prieto LM. Relation between the presence of echocardiographic vegetations and the complication rate in infective endocarditis. Am Heart J 1986; 112: 107-113. doi: 10.1016/0002-8703(86)90687-3.
30. D’Andrea A, Sperlongano S, Formisano T, et al. Stress echocardiography and strain in aortic regurgitation (SESAR protocol): left ventricular contractile reserve and myocardial work in asymptomatic patients with severe aortic regurgitation. Echocardiography 2020; 37: 1213-1221. doi: 10.1111/echo.14804.
31. Alashi A, Khullar T, Mentias A, et al. Long-term outcomes after aortic valve surgery in patients with asymptomatic chronic aortic regurgitation and preserved LVEF. JACC Cardiovasc Imaging 2020; 13: 12-21. doi: 10.1016/j.jcmg.2018.12.021.
32. Malbrain MLNG, De Tavernier B, Haverals S, et al. Executive summary on the use of ultrasound in the critically ill: consensus report from the 3rd Course on Acute Care Ultrasound (CACU). Anaesthesiol Intensive Ther 2017; 49: 393-411. doi: 10.5603/AIT.a2017.0072.
33. Poelaert J, Malbrain MLNG. Cardiac ultrasound: a true haemodynamic monitor? Anaesthesiol Intensive Ther 2018; 50: 303-310. doi: 10.5603/AIT.a2017.0068.
34. Lichtenstein D, Van Hooland S, Elbers P, Malbrain MLNG. Ten good reasons to practice ultrasound in critical care. Anaesthesiol Intensive Ther 2014; 46: 323-335. doi: 10.5603/AIT.2014.0056.
35. Myerson SG. Heart valve disease: investigation by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012; 14: 7. doi: 10.1186/1532-429X-14-7.
36. Cawley PJ, Maki JH, Otto CM. Cardiovascular magnetic resonance imaging for valvular heart disease. Circulation 2009; 119: 468-478. doi: 10.1161/CIRCULATIONAHA.107.742486.
37. Cawley PJ, Hamilton-Craig C, Owens DS, et al. Prospective comparison of valve regurgitation quantitation by cardiac magnetic resonance imaging and transthoracic echocardiography. Circ Cardiovasc Imaging 2013; 6: 48-57. doi: 10.1161/CIRCIMAGING.112.975623.
38. Yoon SH, Kim WK, Dhoble A, et al. Bicuspid aortic valve morphology and outcomes after transcatheter aortic valve replacement. J Am Coll Cardiol 2020; 76: 1018-1030. doi: 10.1016/j.jacc.2020.07.005.
39. Makkar RR, Yoon SH, Leon MB, et al. Association between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke. JAMA 2019; 321: 2193. doi: 10.1001/jama.2019.7108.
40. Mauri V, Frohn T, Deuschl F, et al. Impact of device landing zone calcification patterns on paravalvular regurgitation after transcatheter aortic valve replacement with different next-generation devices. Open Heart 2020; 7: e001164. doi: 10.1136/openhrt-2019-001164.
41. Larroche J, Panh L, Lhermusier T, et al. Impact of aortic valve calcification severity on device success after transcatheter aortic valve replacement. Int J Cardiovasc Imaging 2020; 36: 731-740. doi: 10.1007/s10554-019-01759-7.
42. Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Volta SD. Nifedipine in Asymptomatic Patients with Severe Aortic Regurgitation and Normal Left Ventricular Function. N Engl J Med 1994; 331: 689-694. doi: 10.1056/NEJM199409153311101.
43. Plante E, Gaudreau M, Lachance D, et al. Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation. Can J Physiol Pharmacol 2004; 82: 191-199. doi: 10.1139/y04-005.
44. Plante E, Lachance D, Beaudoin J, et al. Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation. Circ Hear Fail 2009; 2: 25-32. doi: 10.1161/CIRCHEARTFAILURE.108.801548.
45. Lin M, Chiang HT, Lin SL, et al. Vasodilator therapy in chronic asymptomatic aortic regurgitation: Enalapril versus hydralazine therapy. J Am Coll Cardiol 1994; 24: 1046-1053. doi: 10.1016/0735-1097(94)90868-0.
46. Banaszewski M, Rydlewska-Sadowska W, Rubkiewicz S. Captopril or nifedipine? Comparison of rest and exercise acute effects and long-term therapy in chronic isolated asymptomatic moderate to severe aortic regurgitation. J Heart Valve Dis 1998; 7: 488-499.
47. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005; 353: 1342-1349. doi: 10.1056/NEJMoa050666.
48. Alpert JS, Dalen JE, Rahimtoola SH. Valvular heart disease. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
49. Klodas E, Enriquez-Sarano M, Tajik AJ, Mullany CJ, Bailey KR, Seward JB. Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. J Am Coll Cardiol 1997; 30: 746-752. doi: 10.1016/S0735-1097(97)00205-2.
50. Zendaoui A, Lachance D, Roussel É, Couet J, Arsenault M. Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation. Circ Hear Fail 2011; 4: 207-213. doi: 10.1161/CIRCHEARTFAILURE.110.958512.
This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe